Study S001200

A Randomized, Double-blind, Placebo and Positive Drug Parallel-controlled Phase IIa Clinical Study Protocol to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple-dose BGM0504 Injection in Patients With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06974825
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 67
Start: 2023-08-30
Primary completion: 2024-08-13
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:BGM0504 Administered SC; DRUG:Semaglutide Administered SC; DRUG:Placebo Administered SC
Results posted: FALSE

Registered primary outcomes

Change From Baseline in Hemoglobin A1c (HbA1c) [Week 0 to Week 12]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.